Oncolytics Biotech is directing a broad clinical trial program with the objective of developing REOLYSIN® as a human cancer therapeutic. The clinical program includes human trials using REOLYSIN® alone and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration.
| Intravenous administration in combination with paclitaxel and carboplatin |
Phase II head and neck |
U.S. |
Approved |
| Intravenous administration in combination with paclitaxel and carboplatin |
Phase II head and neck |
U.K. |
Ongoing |
| Intravenous administration in combination with cyclophosphamide |
Pancreatic, lung, ovarian |
U.K. |
Ongoing |
| Intravenous administration monotherapy (NCI) |
Phase II melanoma |
U.S. |
Recruiting |
| Intravenous and intraperitoneal administration monotherapy (NCI) |
Phase I/II ovarian |
U.S. |
Ongoing |
| Intravenous administration monotherapy |
Phase II sarcomas |
U.S. |
Ongoing |
| Intravenous administration in combination with gemcitabine |
Pancreatic, lung, ovarian |
U.K. |
Ongoing |
| Intravenous administration in combination with docetaxel |
Bladder, prostate, lung, upper gastro-intestinal |
U.K. |
Ongoing |
| Intravenous administration in combination with paclitaxel and carboplatin |
Melanoma, lung, ovarian |
U.K. |
Ongoing |
| Local therapy in combination with radiation |
Phase II various metastatic tumours, including head & neck |
U.K. |
Ongoing |
| Local therapy in combination with radiation |
Phase I various metastatic tumours |
U.K. |
Complete |
| Infusion monotherapy |
Phase I/II recurrent malignant gliomas |
U.S. |
Ongoing |
| Intravenous administration monotherapy |
Phase I various metastatic tumours |
U.S. |
Complete |
| Intravenous administration monotherapy |
Phase I various metastatic tumours |
U.K. |
Complete |
| Local monotherapy |
Phase I recurrent malignant gliomas |
Canada |
Complete |
| Local monotherapy |
T2 prostate cancer |
Canada |
Complete |
| Local monotherapy |
Phase I trial for various subcutaneous tumours |
Canada |
Complete |